摘要
目的评估EB病毒的Rta蛋白抗体(Rta/IgG)、核抗原抗体(EBNA1/IgA)和病毒衣壳抗原抗体(VCA/IgA)的检测对上海地区鼻咽癌患者的临床诊断价值。方法收集206例病理证实未经治疗的鼻咽癌患者和249例健康成人的血清,均采用酶联免疫吸附试验法定量检测血清中的Rta/IgG、EBNA1/IgA、VCA/IgA抗体水平。结果 206例鼻咽癌患者的EB病毒抗体Rta/IgG、EBNA1/IgA、VCA/IgA的敏感度分别为64.08%、88.35%、86.89%;特异度分别为92.62%、92.92%、95.69%;3种抗体同时阳性的模式在鼻咽癌患者中出现的概率最高(55.83%),而在健康对照组中无一例出现。结论 Rta/IgG、EBNA1/IgA、VCA/IgA的联合检测对上海地区鼻咽癌患者的诊断具有参考价值。
Objective To evaluate the clinical value of Rta/IgG,EBNA1/IgA and VCA/IgA for nasopharyngeal carcinoma patients in Shanghai. Methods Rta/IgG, EBNA1/IgA and VCA/IgA was detected by quantitative enzyme- linked immunosorbent assay in 206 NPC patients and 249 healthy adults. Results The sensitivity rates were 64.08%, 88.35% and 86.89% for Rta/IgG,EBNA1/IgA and VCA/IgA respectively, while the specificity rates were 92. 62%, 92.92% and 95.69% respectively. The results were most common in NPC patients that all three antibodies were posi- tive,but none positive antibodies were seen in healthy adults. Conclusions The combined detection of Rta/IgG, EB- NA1/IgA and VCA/IgA has referential value in diagnosing nasopharyngeal carcinoma patients in Shanghai. （ Chin J Oph- thalmol and Otorhinolaryngo1,2012,12：40-41,46）
出处
《中国眼耳鼻喉科杂志》
2012年第1期40-41,46,共3页
Chinese Journal of Ophthalmology and Otorhinolaryngology
基金
复旦大学附属眼耳鼻喉科医院院级科研基金资助项目(EENT-2010-23
EENT-2009-21)
关键词
鼻咽癌
EB病毒
抗体
nasopharyngeal carcinoma
Epstein-Barr virus
Antibody
